Chang Shao-Hai, Huang Zhuo-Shan, Chen Wei-Liang, Zhou Bin, Zhong Jiang-Long
Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
J Cosmet Dermatol. 2021 Jan;20(1):263-266. doi: 10.1111/jocd.13473. Epub 2020 May 24.
When treating actinic cheilitis (AC), it is essential to minimize the risk of malignant transformation (MT) and maintain lip functionality and cosmesis.
We evaluated the outcomes of vermilionectomy followed by reconstruction of the vermilion mucosa using allograft dermal matrix (ADM) in patients with AC of the lower lip.
We evaluated eight patients with lower lip AC who underwent vermilion mucosa reconstruction using ADM after vermilionectomy. We enrolled five males and three females ranging in age from 55 to 70 years (mean, 62.1 years). The ADM ranged in area from 1.3 × 5.0 to 1.7 × 5.8 cm (median, 1.6 × 5.5 cm). All patients were followed up for at least 3 months postoperatively by a panel of three surgeons who assessed the esthetic results, and orbicularis oris and speech functions.
All patients underwent successful reconstruction of the vermilion mucosa using ADM after vermilionectomy, without complications. The postoperative esthetic results, and the orbicularis oris and speech functions, were satisfactory to excellent in all patients. Patients were followed up for 18-38 months (median, 26.1 months). No MT or recurrence was noted.
Vermilionectomy followed by reconstruction of the vermilion mucosa with ADM is safe and feasible for AC patients.
治疗光化性唇炎(AC)时,将恶性转化(MT)风险降至最低并维持唇部功能和美观至关重要。
我们评估了下唇AC患者行唇红切除术,然后使用同种异体真皮基质(ADM)重建唇红黏膜的效果。
我们评估了8名下唇AC患者,他们在唇红切除术后使用ADM进行唇红黏膜重建。我们纳入了5名男性和3名女性,年龄在55至70岁之间(平均62.1岁)。ADM面积为1.3×5.0至1.7×5.8平方厘米(中位数为1.6×5.5平方厘米)。所有患者术后至少随访3个月,由三名外科医生组成的小组评估美学效果、口轮匝肌功能和言语功能。
所有患者在唇红切除术后使用ADM成功重建唇红黏膜,无并发症。所有患者的术后美学效果、口轮匝肌功能和言语功能均为满意至优秀。患者随访18至38个月(中位数为26.1个月)。未发现MT或复发。
对于AC患者,唇红切除术后用ADM重建唇红黏膜是安全可行的。